News - page 3 - Healixia

October 3, 2022

Flash VIG-news : Dispensation of pholcodine-containing medicinal products suspended due to the risk of allergic cross-reactivity with neuromuscular blocking agents

Due to concerns about the risk of anaphylactic reactions, the dispensation of pholcodine-containing medicinal products is suspended from 1 October 2022.

Source: FAMHP

September 30, 2022

Limited availability of thrombolytics: recommendations for hospital pharmacists and specialist physicians.

België wordt net als andere Europese landen geconfronteerd met kritieke beschikbaarheidsproblemen van trombolytica, dat zijn geneesmiddelen om bloedstolsels op te lossen. Het FAGG doet aanbevelingen rond het rationeel gebruik van deze geneesmiddelen en prioritisering van indicaties. De stock binnen de ziekenhuizen wordt opgevolgd en een noodvoorraad zal worden voorzien.

À l’instar d’autres pays européens, la Belgique est confrontée à des problèmes de disponibilité critique de thrombolytiques (médicaments servant à dissoudre les caillots sanguins). L’AFMPS formule des recommandations sur l’usage rationnel de ces médicaments et la priorisation d’indications. Le stock hospitalier fait l’objet d’un suivi et un stock d’urgence sera constitué.

Source: FAMHP

September 29, 2022

Ozempic: recommendations for doctors (specialists) and (hospital) pharmacists due to limited availability

There is limited availability of the medicine Ozempic (semaglutide-based solution for subcutaneous injection) due to an acute increase in demand. This limited availability will certainly last until early 2023. Experts from the FAMHP's Unavailability Task Force give recommendations.

Source: FAMHP

September 29, 2022

Warning against the use of illegal TKTX ointment after applying tattoos

The FAMHP wants to warn consumers in Belgium not to use TKTX ointment, an illegal pain-relieving cream. It is mainly used to alleviate pain when applying a tattoo, permanent make-up ... TKTX ointment is not licensed in Belgium or Europe and therefore no guarantees can be given with regard to the composition, safety, quality or efficiency of this illegal medicine.

Source: FAMHP

September 15, 2022

PRAC September 2022 –Reviews of topiramate and pholcodine medicines started

During the September 2022 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has started a referral of topiramate and also started a referral of pholcodine medicines.

Source: FAMHP

September 12, 2022

IFAPP Today newsletter - September 2022

Source: IFAPP

Please find here the link to the IFAPP TODAY newsletter of September 2022.

August 30, 2022

Coronavirus: overview of side effects COVID-19 vaccines from August 25, 2022

Het volgende cumulatief overzicht van de bijwerkingen die zijn gemeld na toediening van een COVID-19-vaccin in België zal worden gepubliceerd op 24 november 2022.

Le prochain aperçu cumulatif des effets indésirables signalés suite à l'administration d'un vaccin contre la COVID-19 en Belgique sera publié le 24 novembre 2022.

Source: FAMHP

August 30, 2022

The FAMHP is looking for a new administrator-general

The mandate of Xavier De Cuyper, administrator-general of the FAMHP has ended. Xavier De Cuyper has been the agency's top manager since 2007 and has reached the age limit for holding a mandate within the federal government. A new selection procedure to appoint his successor was published by the Federal Government Selection Office (Selor).

Source: FAMHP

August 30, 2022

Accelerating Clinical Trials in the EU: publication of 2022-2026 workplan

The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the 2022-2026 workplan of the Accelerate Clinical Trials in the EU (ACT EU) initiative. The workplan has been prepared based on the recommendations of the European medicines agencies network strategy to 2025 and the European Commission’s Pharmaceutical Strategy for Europe.

August 19, 2022

Call for candidates pilot project “e-PIL”: paper leaflet makes way for electronic leaflet

The FAMHP supports the pilot project “e-PIL” initiated by the pharmaceutical industry in Belgian and Luxembourg hospitals. In the context of this project, the package leaflet of certain medicines on the market in Belgium and Luxembourg is no longer put on paper in the box of the medicine, but is only available online on controlled websites.

Source: FAMHP